Targeting Cadherin-17 for gastrointestinal cancer treatment
Targeting Cadherin-17 for gastrointestinal cancer treatment
Cadherin-17 (CDH17), also known as liver-intestine cadherin (LI-Cadherin), is a cell adhesion protein predominantly expressed in normal intestinal epithelium and pancreatic ducts, as well as in gastrointestinal cancers such as gastric cancer (GC), colorectal cancer (CRC), and pancreatic adenocarcinoma (PDAC). High levels of Cadherin-17 have been linked to metastasis and poor prognosis. Cadherin-17 is considered as a target for diagnostics and therapeutics. arigo offers specific Cadherin-17 antibody [SQab30334] (ARG67064) to facilitate the detection of Cadherin-17.
|
Cadherin-17 plays a critical role in cancer metastasis, particularly in gastric, colorectal, liver, and breast cancers. In gastric cancer, Cadherin-17 induces lymphatic metastasis via NFkB pathway. In colorectal cancer, Cadherin-17 facilitates liver metastasis via α2β1 integrin-FAK axis. arigo offers a series of tools to accelerate the research of Cadherin-17 and metastasis.
EMT Marker Antibody
|
Phospho-FAK Antibody
|
Phospho-NFkB Antibody
|
|
Cadherin-17 is a therapeutic target as it promotes cancer growth and metastasis. M13 phage display is a powerful tool for the development of therapeutic antibodies. arigo offers the best M13 g8p antibody [SQab21250] (ARG66893) and Cadherin-17 protein to facilitate the development of CDH17-targeting therapies, as well as the kits to validate the cytotoxicity.
Cadherin-17 protein |
M13 antibody | Validation |
|
Histological markers of gastrointestinal cancer
CK7 / CK20 Antibody Duo (ARG30318)![]() |
CDX2 antibody [SP54] (ARG52839)![]() |
Villin antibody [SQab19149] (ARG66631)![]() |
CAF Marker Antibody Panel (ARG30347) ![]() |
M1/ M2/ TAM Antibody Panel (ARG30333) ![]() |
![]() |